Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MNCs in Hormone-resistant or Hormone-dependent Ulcerative Colitis
NCT04882683Unknown
- Sponsor
- Shandong Qilu Stem Cell Engineering
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of umbilical cord blood mononuclear cells in ulcerative colitis (UC) (2 arms), sponsored by Shandong Qilu Stem Cell Engineering. Primary endpoints: Clinical efficacy rate and Clinical response rate. Status: unknown.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04882683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882683.